MarketCap
Facebook
X
Telegram
Immutep Limited Revenue | IMMP
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Immutep Limited
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10.3 M | 7.84 M | 5.2 M | 6.76 M | 3.97 M | 16.5 M | 7.49 M | 7.35 M | - | 175 K | - | - | - | 1.52 M | - |
Annual performance
Select metrics to display
All numbers in AUD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 16.5 M | 175 K | 6.71 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Biotechnology industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Timber Pharmaceuticals
TMBR
|
83.2 K | - | - | $ 717 K |  USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
178 M | - | -15.15 % | $ 60.3 M |  Britain |
 |
AVEO Pharmaceuticals
AVEO
|
17.6 M | - | - | $ 521 M | USA |
 |
Advaxis
ADXS
|
13 K | - | -9.65 % | $ 45.9 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
277 M | - | - | $ 2.02 B | USA |
 |
Lineage Cell Therapeutics
LCTX
|
14.6 M | $ 0.95 | -2.17 % | $ 219 M | USA |
 |
Codiak BioSciences
CDAK
|
22.9 M | - | -55.98 % | $ 2.15 M | USA |
 |
Cerevel Therapeutics Holdings
CERE
|
2.72 M | - | - | $ 7.29 B | USA |
 |
Checkpoint Therapeutics
CKPT
|
41 K | - | - | $ 169 M | USA |
 |
Sage Therapeutics
SAGE
|
41.2 M | - | - | $ 527 M | USA |
 |
Taro Pharmaceutical Industries Ltd.
TARO
|
573 M | - | - | $ 1.62 B |  Israel |
 |
Horizon Therapeutics Public Limited Company
HZNP
|
3.63 B | - | - | $ 26.6 B |  Irlanda |
 |
Seelos Therapeutics
SEEL
|
2.2 M | - | -47.76 % | $ 6.27 M | USA |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
268 M | $ 314.78 | 2.73 % | $ 6.09 B | USA |
 |
Longeveron
LGVN
|
1.2 M | $ 1.43 | -4.67 % | $ 25.1 B | USA |
 |
Legend Biotech Corporation
LEGN
|
627 M | $ 18.63 | -2.0 % | $ 6.87 B | USA |
 |
Baudax Bio
BXRX
|
1.27 M | - | 0.59 % | $ 63 K | USA |
 |
Calithera Biosciences
CALA
|
9.75 M | - | -10.95 % | $ 876 K | USA |
 |
ChemoCentryx
CCXI
|
2.32 M | - | - | $ 3.74 B | USA |
 |
Avid Bioservices
CDMO
|
140 M | - | - | $ 789 M | USA |
 |
Zosano Pharma Corporation
ZSAN
|
785 K | - | 7.23 % | $ 2.72 M | USA |
 |
Spectrum Pharmaceuticals
SPPI
|
10.1 M | - | - | $ 189 M | USA |
 |
VBI Vaccines
VBIV
|
8.68 M | - | -50.87 % | $ 1.09 M | USA |
 |
CTI BioPharma Corp.
CTIC
|
53.9 M | - | - | $ 1.2 B | USA |
 |
IVERIC bio
ISEE
|
210 M | - | - | $ 5.51 B | USA |
 |
Myovant Sciences Ltd.
MYOV
|
231 M | - | -0.04 % | $ 2.62 B | USA |
 |
Eli Lilly and Company
LLY
|
65.2 B | $ 1 270.75 | -1.11 % | $ 1.14 T | USA |
 |
Metacrine
MTCR
|
1.45 M | - | - | $ 24.2 M | USA |
 |
Molecular Templates
MTEM
|
18.8 M | - | -23.43 % | $ 495 K | USA |
 |
Lipocine
LPCN
|
1.98 M | $ 1.6 | -1.23 % | $ 8.72 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
163 M | - | - | $ 2.18 B | USA |
 |
Entasis Therapeutics Holdings
ETTX
|
7 M | - | - | $ 105 M | USA |
 |
Aptevo Therapeutics
APVO
|
3.11 M | $ 1.6 | -0.93 % | $ 505 K | USA |
 |
Liquidia Corporation
LQDA
|
158 M | $ 38.86 | 6.91 % | $ 3.34 B | USA |
 |
Aquestive Therapeutics
AQST
|
44.5 M | $ 4.08 | 0.74 % | $ 436 M | USA |
 |
Global Blood Therapeutics
GBT
|
195 M | - | - | $ 4.62 B | USA |
 |
Idera Pharmaceuticals
IDRA
|
4.86 M | - | -23.04 % | $ 26.6 M | USA |
 |
Infinity Pharmaceuticals
INFI
|
2.59 M | - | -46.98 % | $ 3.57 M | USA |
 |
Novan
NOVN
|
23.7 M | - | -24.84 % | $ 2.64 M | USA |
 |
NanoString Technologies
NSTG
|
127 M | - | -37.43 % | $ 5.1 M | USA |
 |
Orgenesis
ORGS
|
1.04 M | - | -33.86 % | $ 61.2 M | USA |
 |
Humanigen
HGEN
|
2.51 M | - | -81.12 % | $ 4.28 M | USA |
 |
Sorrento Therapeutics
SRNE
|
62.8 M | - | -29.58 % | $ 126 M | USA |
 |
Surface Oncology
SURF
|
30 M | - | - | $ 59.7 M | USA |